Drug
Henagliflozin Daily
Henagliflozin Daily: highest development phase Post-Market, developed by Jiangsu Hengrui Medicine. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| Henagliflozin 10 mg daily NCT06762223 | Post-Market | Metabolic Dysfunction-associated Steatotic Liver Disease |
Latest
No recent events.
Follow Henagliflozin Daily on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.